Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
26.06. | Erasca, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
02.06. | Erasca Announces Clearance Of IND Application By FDA For ERAS-4001 | - | RTTNews | ||
02.06. | FDA clears Erasca's new cancer drug applications | 1 | Investing.com | ||
ERASCA Aktie jetzt für 0€ handeln | |||||
13.05. | Erasca, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
13.05. | Erasca, Inc.: Erasca Reports First Quarter 2025 Business Updates and Financial Results | 81 | GlobeNewswire (Europe) | Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026... ► Artikel lesen | |
13.05. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.05. | Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset | 1 | FierceBiotech | ||
13.05. | FDA clears Erasca's new cancer drug ERAS-0015 | 1 | Investing.com | ||
29.04. | Erasca, Inc.: Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
26.03. | Raymond James sets $5 target for Erasca stock, cites valuation gap | 5 | Investing.com | ||
25.03. | Erasca, Inc.: Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting | 1 | GlobeNewswire (USA) | ||
20.03. | Erasca GAAP EPS of -$0.11 beats by $0.02 | 3 | Seeking Alpha | ||
20.03. | Erasca, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
20.03. | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results | 565 | GlobeNewswire (Europe) | Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well... ► Artikel lesen | |
12.11.24 | Erasca, Inc.: Erasca Reports Third Quarter 2024 Business Updates and Financial Results | 520 | GlobeNewswire (Europe) | Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution... ► Artikel lesen | |
12.08.24 | Erasca, Inc.: Erasca Reports Second Quarter 2024 Business Updates and Financial Results | 206 | GlobeNewswire (Europe) | In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors Initiated... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,15 | +0,16 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
CUREVAC | 4,660 | -0,09 % | EQS-News: CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an
08.08.2025 / 02:15 CET/CEST
Für... ► Artikel lesen | |
MODERNA | 22,460 | +0,04 % | Moderna nach Zahlen: Ist die Zukunft düster? | Moderna galt während der COVID-19-Pandemie als einer der großen Gewinner und avancierte mit seiner mRNA-Technologie und dem Impfstoff SpikeVax zu einem der führenden Biotechnologieunternehmen der Welt.... ► Artikel lesen | |
PAION | 0,010 | 0,00 % | Unglaubliche Prognose für Montag setzt Paion Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
NOVAVAX | 7,220 | +0,36 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
4SC | 0,550 | +3,77 % | PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025 | DJ PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Planegg-Martinsried (pta000/08.08.2025/07:30... ► Artikel lesen | |
NANOREPRO | 1,600 | +3,56 % | EQS-DD: NanoRepro AG: Lisa Jüngst, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
05.08.2025 / 14:00... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,210 | 0,00 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
INFLARX | 0,700 | +0,57 % | InflaRx N.V.: InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update | INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,361 | -2,96 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,228 | +1,32 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
DYNAVAX | 10,100 | +13,87 % | Dynavax Technologies: Dynavax Reports Second Quarter 2025 Financial Results | Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growth
Refines full year 2025 HEPLISAV-B net product revenue... ► Artikel lesen | |
REDHILL BIOPHARMA | 1,160 | -0,85 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen |